Epigenomics (EPGNY) Stock Price, News & Analysis

Company Overview

Epigenomics AG is a molecular diagnostics company headquartered in Berlin, Germany, specializing in the development and commercialization of epigenetic biomarker assays for the early detection of cancer. Founded in 1998, the firm leverages proprietary DNA methylation technology to identify tumor-derived DNA fragments in body fluids, with the aim of providing minimally invasive screening and diagnostic tests that improve patient outcomes.

The company’s flagship product, Epi proColon, is a blood-based screening test designed to detect methylated SEPT9 DNA, an established biomarker for colorectal cancer. This assay has been approved for use in multiple markets, including the European Union and the United States, and offers an alternative to traditional fecal screening methods. In addition to colorectal applications, Epigenomics is advancing a pipeline of next-generation assays targeting other indications such as lung and pancreatic cancer, in collaboration with academic and industry partners.

Epigenomics serves a global customer base through a network of distribution and licensing agreements, with a focus on European and North American clinical laboratories and healthcare providers. The company maintains strategic partnerships across Asia and the Middle East to facilitate market entry and local regulatory approval. Its products are supported by extensive clinical studies and real-world performance data, reinforcing its position in the oncology diagnostics landscape.

Under the guidance of an experienced management team with deep expertise in molecular biology, oncology research and commercial diagnostics, Epigenomics continues to expand its R&D capabilities and global footprint. The board of directors and scientific advisory board include leading experts in cancer epigenetics, ensuring that the company remains at the forefront of innovation in non-invasive cancer testing and translational biomarker discovery.

Key Stats

• Today's Range: $2.39 to $2.39
• 50-Day Range: $2.39 to $2.39
• 52-Week Range: $2.01 to $2.39
• Volume: N/A
• Average Volume: 100 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

EPGNY Stock Analysis - Frequently Asked Questions

How have EPGNY shares performed this year?

Epigenomics' stock was trading at $2.39 at the start of the year. Since then, EPGNY stock has increased by 0.0% and is now trading at $2.39.

How do I buy shares of Epigenomics?

Shares of EPGNY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Diagnostics & Research
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:EPGNY
• CIK: N/A
• Web: www.epigenomics.com
• Phone: (493) 024-3450
• Fax: N/A
• Employees: 32
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A